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In the absence of effective pharmacotherapy for diabetes there has been an increase in the use of, and research into, alternative treatment strategies.
These include exercise, dietary interventions and the use of supplements including extracts of ginseng. Two separate, placebo-controlled, double-
blind, cross-over studies investigating the effects of chronic ingestion of Panax ginseng (study 1 used G115, study 2 used Cheong Kwan Jang) on
glycated Hb (HbA1c; study 1, n 18; study 2, n 11), fasting plasma insulin (study 1, n 17; study 2, n 12), fasting plasma glucose and postprandial
response (following breakfast) (study 1, n 23; study 2, n 14) in healthy volunteers are reported. In both studies it was found that Panax ginseng had
no effect on any gluco-regulatory parameter investigated. These results are not consistent with those reported for a diabetic sample (albeit using
slightly different outcomes). These results would suggest that chronic use of Panax ginseng by non-diabetic individuals will have little long-term
effect on glucose regulation. The benefits to glucose regulation associated with long-term ginseng use may only be present in populations with
compromised glucose control; however, further research is needed to confirm such a speculation.
Panax ginseng: Glucose response: Insulin: Glycated Hb levels
The increasing incidence of diabetes(1) is a global concern,
especially when the available treatment appears to be insuffi-
cient to halt the disease progression and the majority of type 2
diabetes patients eventually require insulin therapy(2). It is
estimated that diabetes is likely to be the fifth leading cause
of death globally(3). These considerations have led to an
increase in the use of, and research into, alternative treatment
strategies, including exercise and dietary interventions. The
latter include herbal supplements including extracts of
ginseng.
The term ‘ginseng’ usually refers to the dried root of several
species in the plant genus Panax (Araliaceae family). The two
most common species are Panax ginseng (Asian ginseng) and
Panax quinquefolius (American ginseng), both of which have
documented acute hypoglycaemic effects(4–15). The acute
hypoglycaemic effects of Panax quinquefolius have been
demonstrated in a series of randomised, placebo-controlled
studies in diabetic and healthy human subjects. Compared
with placebo, reductions in the blood glucose response to a
25 g (and 75 g(15)) glucose challenge have been reported
during a 120min oral glucose tolerance test in both diabetic
patients who had ingested 3, 6 and 9 g(9,10), and healthy
participants administered 1, 2, 3 and 9 g Panax quinquefo-
lius (9,11,15). However, Sievenpiper et al. (16) failed to report
any hypoglycaemic effect of 6 g Panax quinquefolius,
administered 40min before, or concurrently with, a 75 g
glucose drink in twelve healthy volunteers. Additionally, Sie-
venpiper et al. (17) reported that there was no effect of eight
other widely used ginseng types (Sanchi, Siberian, American,
Asian, Korean red, Japanese, wild American and Vietnamese)
on indices of glycaemic control following a 75 g oral glucose
tolerance test in healthy volunteers. However, an extract of
Panax ginseng was associated with increased blood glucose
levels and insulin response following the glucose load(17).
With regards to Panax ginseng, a further two studies have
reported significant reductions in fasting blood glucose
levels measured 1 h after a single dose of 200 and 400mg in
healthy volunteers but no effect on postprandial glucose (fol-
lowing a 25 g glucose drink) response(13,14). While there are
discrepancies between the findings of the acute studies,
these may be attributable to differences in populations
(healthy and diabetic), dietary states (fasting and postprandial)
and ginseng types (Asian and American). Additionally, treat-
ment doses, timing and the level of glucose loads have dif-
fered between studies. Nevertheless there is a growing
consensus that both Panax ginseng and Panax quinquefolius
are capable of acute glycaemic modulation in both healthy
and diabetic populations.
In line with the acute effects briefly delineated earlier,
ginseng may also be promising as a potential chronic treatment
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in diabetes. A reduction in fasting blood glucose levels and gly-
catedHb (HbA1c; an index of blood glucose over the past month
or so) were reported following 8 weeks of administration of 100
and 200mg/d of an unspecified ginseng extract in eighteen par-
ticipants with type 2 diabetes mellitus(18). Similarly, Tetsutani
et al. (8) reported that 24 months of treatment with 3–4·5 g/d
Korean red Panax ginseng decreased HbA1c in thirty-four
type 2 diabetics compared with controls. With regards to
Panax quinquefolius, a decrease in fasted blood glucose and
HbA1c has been reported in twenty-four type 2 diabetic patients
following 8 weeks of administration of 1 g of a proprietary gin-
seng extract, taken 40min before each meal(10). Similarly,
Vuksan et al. (12) reported improved glucose regulation follow-
ing chronic supplementation with Panax ginseng. Nineteen
well-controlled type 2 diabetes patients received Panax ginseng
for 12 weeks. Panax ginseng (2 g) was ingested 40min before
each of three daily meals. Between-groups comparisons were
made on eleven indices of glucose regulation, presented under
three categories: (1) HbA1c; (2) fasting indices (fasting
plasma glucose, fasting plasma insulin and homeostasis model
assessment (HOMA)); and (3) postprandial response to a 75 g
oral glucose tolerance test (mean plasma glucose, mean
plasma insulin, peak plasma glucose, peak plasma insulin,
plasma glucose area under the curve, plasma insulin area
under the curve and oral glucose tolerance test-insulin sensi-
tivity index). Results indicate that following 12 weeks of
Panax ginseng supplementation there was no difference in
HbA1c, fasting plasma glucose or peak plasma glucose. All
other indices of glucose regulation that were measured were
improved in the treatment group.
As with the series of acute studies it is of clinical interest
to investigate the glycaemic effects following chronic inges-
tion of ginseng, in a healthy non-diabetic population.
Additionally, given that no study to date has investigated
the acute glycaemic effects beyond the clinically relevant
2 h post-dose measurement point, it is of interest to investi-
gate ginseng’s glycaemic effects beyond this point. Specifi-
cally, to investigate whether glucose levels continue to fall,
beyond normoglycaemic levels, once they have returned to
baseline levels.
The present paper reports, for the first time, the results from
two double-blind, placebo-controlled, balanced, cross-over
studies. These studies assessed the effects of 4 and 8 weeks of
ingestion of two Panax ginseng extracts on indices of
glycaemic regulation (HbA1c, fasting plasma insulin, fasting
plasma glucose) and at 3 h post-breakfast, in healthy volunteers.
Participants and methods
Participants
Both study 1 and study 2 were approved by the Northumbria
University Division of Psychology Ethics committee and con-
ducted in accordance with the Declaration of Helsinki. Prior to
participation each participant gave informed consent and com-
pleted a medical health questionnaire. All participants reported
that they were in good health (free from heart disorders, res-
piratory disorders, high blood pressure, epilepsy, panic attacks
and diabetes) and were not taking any illicit social drugs.
Additionally, they were free from ‘over-the-counter’ or pre-
scribed medications, with the exception, for some female
volunteers, of the contraceptive pill. Heavy smokers (more
than ten cigarettes per day) were excluded from both studies.
All participants fell within the normal healthy BMI range (par-
ticipants who fell outside the normative range were excluded
from the study). All participants fasted overnight and were
alcohol- and caffeine-free for 12 h prior to, and during,
assessment days. In both studies volunteers were paid £150
for participation. No participant took part in both studies.
Study 1. Thirteen female and twelve male volunteers,
recruited through local media advertisements, participated in
study 1. Due to a number of missing data points (blood
could not be collected or finger prick analysis reported an
error) the dataset was reduced to twenty-three (twelve
males, eleven females; mean age 35·6 (SD 10·8) years) for
finger prick blood glucose levels; reduced to eighteen (ten
males, eight females; mean age 33·3 (SD 10·4) years) for
HbA1c and further reduced to seventeen (eight males, nine
females; mean age 32·8 (SD 9·7) years) for fasting plasma
insulin. Treatment compliance was assessed through verbal
communication: participants were asked to record any days
that they forgot to take their dose. Two participants reported
forgetting to take their dose when in the placebo condition.
A further two participants reported that they forgot to take
their dose when in the active treatment condition. One partici-
pant forgot to take day 14’s treatment dose while the second
forgot to take the treatment on day 6. All participants were
blind to the treatment condition throughout the study and all
were included in the analysis.
Study 2. Thirteen female and five male volunteers,
recruited through local media advertisements, participated in
study 2. Due to a number of missing data points (blood
could not be collected or finger prick analysis reported an
error) the dataset was reduced to fourteen (five males, nine
females; mean age 38·4 (SD 10·6) years) for finger prick
blood glucose levels; reduced to twelve (four males, eight
females; mean age 40·75 (SD 9·64) years) for fasting plasma
insulin and further reduced to eleven (three males, eight
femles; mean age 41·5 (SD 9·7) years) for HbA1c. Treatment
compliance was assessed through verbal communication: par-
ticipants were asked to record any days that they forgot to take
their dose. One participant reported a failure to take one day’s
dose when in the active treatment condition (day 17 of the
treatment regimen) due to unforeseen working commitments.
Participants were blind to their treatment condition throughout
the study and all participants were included in the analysis.
Physiological measures
Glycated Hb. A 2·5ml venous blood sample was taken from
the arm of each participant at the beginning of each testing
day (days 1, 29, 57). Blood samples were collected in a
monovette containing EDTA and whole blood was stored at
2208C prior to analysis. HbA1c levels were established
using a Tosoh G7 HbA1c analyser. This system uses a
cation exchange column to separate Hb components by differ-
ent ionic charge. The various components of Hb, including
A1c, are separated into six fractions and assayed.
Fasting plasma insulin. A 2·5ml blood sample was taken
from the arm of each participant at the beginning of each test-
ing day (days 1, 29, 57). Blood samples were collected in
a serum gel monovette and immediately centrifuged for
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10min at 3000 rpm at 78C using an Allegra X-22R centrifuge
supplied by Beckman Coulter. The resulting supernatant was
poured off into an Eppendorf tube and kept at 2208C prior
to analysis. Blood insulin levels were established using a
solid-phase enzyme-amplified sensitivity immunoassay (Bio-
Source INS-EASIA) performed on microtitre plates. The
assay uses monoclonal antibodies directed against distinct
epitopes of insulin.
Capillary finger prick blood samples. Capillary finger
prick blood glucose was sampled pre-dose and 3 h post-dose
on days 1, 29 and 57. Blood glucose levels were measured
using a Reflotron Plus diagnostic machine and Reflotron test
sticks, CV is 1·8% in the normal range and 2·5% in the
normal range for repeatability (within-series imprecision)
and reproducibility (day-to-day imprecision), respectively
(Roche Diagnostics, Germany). The reliability of the test has
previously been confirmed(19).
Treatments. Active treatments and placebo capsules
(study 1, containing soyabean oil, partly hydrogenated soya-
bean oil, yellow beeswax, lecithin, yellow iron oxide; study
2, information is not available), matched for size, colour, opa-
city and odour were provided by the manufacturers. Prior to
the commencement of each study, a disinterested third party,
who had no other involvement in the study, prepared the treat-
ments for each individual participant (treatment order was
counterbalanced and participants were randomly allocated to
a treatment regimen) and sealed them in containers marked
only with the participant code and study day numbers (1–
29; 30–57). Each participant ingested two capsules every
day for 57 d (on days 1, 29 and 57 treatments were ingested
in the laboratory). The individual capsules contained either
an inert placebo or 100mg Panax ginseng extract G115 in
study 1 (Pharmaton SA, Lugano, Switzerland) or 100mg
Panax ginseng extract in study 2 (Cheong Kwan Jang,
Korea Ginseng Corporation, Seoul, Korea). Depending on
the condition to which the participant was allocated, the
combination of capsules treatments corresponded to a dose of
0mg (placebo) or 200mg G115 (study 1) or 200mg Korean
ginseng (study 2).
Procedure
In both study 1 and study 2 participants received each treat-
ment (placebo and 200mg Panax ginseng) for 57 d in total,
with an intervening wash-out period of 27 d between treat-
ments when all participants received placebo. Treatment
order was counterbalanced across participants and they were
randomly allocated to a treatment regimen. Capillary finger
prick blood and venous whole blood (2 £ 2·5ml) was sampled
on each study day (days 1, 29, 57), in both treatment regimens
(placebo and 200mg), in study 1 and study 2, immediately
prior to the ingestion of that day’s dose and then again 3 h
post-dose (finger prick sample only). Before leaving the lab-
oratory on each study day, participants were provided with a
container containing treatments for each day (either days
2–28 or days 30–56) until the next laboratory visit. Treat-
ments on days 1, 29 and 57 of each period were consumed
in the laboratory. All participants were in an overnight
fasted state during pre-dose blood sampling and each partici-
pant consumed an identical breakfast on each of their study
days, immediately after treatment ingestion (see Fig. 1). Typi-
cal light breakfasts consisted of toast, cereal or fruit (self-
selected by the participant) and varied between participants.
Statistics
All data were analysed using the Minitab statistical package
version 13.1 (Minitab Ltd, Coventry, UK). Treatment
effect on HbA1c and plasma insulin were investigated by
two-way repeated measures ANOVA (treatment (placebo,
200mg) £ day (1, 29 570)) to reveal any chronic effects. Treat-
ment effects on capillary finger prick blood glucose levels
were investigated by three-way repeated measures ANOVA
(treatment (placebo, 200mg) £ day (1, 29, 57) £ session
Fig. 1. Timelines of the study. Participants received either placebo (- - -) or 200 mg ginseng (—) during the first arm of the study (weeks 0–8), and the opposite
treatment in the second arm (weeks 12–20). All participants received placebo during the washout period (beginning of week 9 to end of week 12). Testing days
took place on days 1, 29 and 57 of each arm.
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(pre, post)) to reveal any acute, chronic and superimposed
(i.e. acute upon chronic) effect.
Results
Glycated Hb
There was no significant main effect of treatment or inter-
action with treatment revealed in either study 1 or study 2
(see Table 1).
Fasting plasma insulin
There was no significant main effect of treatment or inter-
action with treatment revealed in either study 1 or study 2
(see Table 1).
Capillary finger prick blood glucose
There was no significant main effect of treatment or significant
interaction with treatment revealed in either study 1 or study 2
(see Table 2).
Discussion
To our knowledge, the present study is the first to assess the
effect of chronic ingestion of Panax ginseng on indices of glu-
cose regulation in healthy volunteers. The results show that
200mg Panax ginseng from two different sources, ingested
daily for 4 and 8 weeks, has no effect on indices of glucose
regulation (HbA1c, fasting plasma insulin, fasting plasma glu-
cose). The results also suggest that there is no effect at the
acute 3 h measurement point that follows a light breakfast,
measured 180min after ginseng ingestion, in healthy
volunteers.
To date there have been a number of studies that have
investigated the glycaemic effects, following chronic inges-
tion, of different members of the genus Panax family in a dia-
betic population. However, only three studies(8,10,12) give
sufficient detail, relating to the extract and dose used, to
allow discussion. Two of the three studies have utilised
Panax ginseng. The results of the present study are at odds
with both of these previous studies. For example, in the
first, Tetsutani et al. (8) reported significant reductions in
HbA1c following 3–4·5 g Panax ginseng administered for
24 months. In the second Vuksan et al. (12) reported significant
improvements in nine of the eleven indices of glucose regu-
lation measured, following 12 weeks of Panax ginseng sup-
plementation (6 g/d). Interestingly, the two indices that
Vuksan failed to find improvements on (i.e. HbA1c and fast-
ing blood glucose levels) are two of the four indices of glucose
regulation measured in the present study (however, it should
be noted that both previous studies utilised diabetic popu-
lations, therefore direct comparisons between the present
study, utilising non-diabetics, and these previous studies are
problematic). In the third study, Vuksan et al. (10) reported
the effect following 8-week administration of Panax quinque-
folius (1 g/d) and reported significant reductions in HbA1c and
fasting blood glucose levels (again comparisons are proble-
matic as differences between ginseng type and the population
studied may explain the different profile of results). Given the
caution advised earlier, the most parsimonious explanation for
the discrepancies between the present study and those reported
in a diabetic population would be differences in study dur-
ation, the extract under investigation and differences in the
population studied. Further research is needed to investigate
these effects in a non-diabetic population. Additionally, cau-
tion is advised when interpreting the present results as there
are a number of limitations; the present study had reduced
sample size as a result of missing data; the storage of the
blood samples (i.e. 2208C) is not recommended as the stab-
ility of the sample is questionable and finally there is an
imbalance of the number of males and females in study 2.
The present study also allowed further consideration of the
acute glycaemic effects of Panax ginseng ingestion that fol-
lowed a light breakfast. The results revealed no difference
between treatment and placebo, measured 180min after gin-
seng ingestion. The rationale for this measurement point
stems from an interest to investigate if the hypoglycaemic
effects (previously reported) would persist beyond the clini-
cally relevant 2 h measurement point. This is of interest as
no study to date has investigated the glycaemic effects
beyond this 2 h point. It is possible that ginseng continues to
lower blood glucose levels past normoglycaemic levels
Table 1. Glycated Hb (HbA1c) and fasting plasma insulin levels following 29 and 57 d of consecutive ginseng
ingestion (200 mg/d) for two different ginseng extracts in healthy volunteers*
(Mean values with their standard errors)
Day 1 Day 29 Day 57
Treatment Mean SE Mean SE Mean SE
HbA1c (% of total)
Study 1 (n 18) Placebo 5·45 0·08 5·32 0·08 5·24 0·08
200 mg 5·36 0·07 5·38 0·09 5·32 0·09
Study 2 (n 11) Placebo 5·45 0·11 5·24 0·09 5·21 0·08
200 mg 5·49 0·11 5·41 0·12 5·23 0·10
Plasma insulin (mIU/ml)
Study 1 (n 17) Placebo 10·51 0·98 13·85 1·36 13·66 0·94
200 mg 11·03 0·73 12·93 2·04 14·13 2·90
Study 2 (n 12) Placebo 13·99 1·53 13·12 0·94 13·57 1·63
200 mg 13·98 1·16 14·57 1·09 13·12 0·81
* For details of subjects and procedures, see Participants and methods. Study 1 used G115 ginseng and study 2 used Cheong Kwan Jang ginseng.
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(normoglycaemic levels are typically reached by 120min). As
the present study is the first study to measure the acute gluco-
regulatory effects of ginseng beyond this 2 h point it is not
valid to compare results of the present study to those that
have measured the glycaemic effect during an oral glucose tol-
erance test (incorporating the 2 h measurement point) and the
fact that participants’ blood glucose levels will have returned
to normoglycaemic levels. Further research is needed.
The present results may give insight into the safety of
Panax ginseng use in healthy non-diabetic populations.
Despite there being no health risk associated with the acute
postprandial hypoglycaemic properties of ginseng (these
effects being considered advantageous in diabetic popu-
lations), there may be some concerns relating to the duration
of these effects and further concerns when such products are
ingested in a fasted state. One might assume that the actions
of glucagon would counteract any further hypoglycaemic
effect, once glucose levels have returned to normal levels fol-
lowing a challenge, at later time-points. However, such a con-
trol mechanism did not appear in a group of healthy volunteers
whose fasted blood glucose level dropped by as much as 20%,
when measured 120min after Panax ginseng ingestion (no
later time-points were measured)(13). Therefore, the present
results suggest that ginseng’s acute hypoglycaemic effect
does not continue once glucose levels have normalised, after
consuming a light breakfast (obviously, we cannot comment
if ginseng lowered blood glucose levels at earlier time-
points and we cannot comment if this effect would be the
same, if participants were fasted overnight). This is of particu-
lar interest as Panax ginseng is by far the most commonly
consumed member of the genus, not only for its purported
health benefits but also for its effect on human behaviour(20).
The mechanisms underlying ginseng’s glycaemic effects are
not clear at present. However, animal and human data would
suggest three possible mechanisms that could potentially
account for the modulation in blood glucose levels: (1) modu-
lation of glucose uptake; (2) modulation of glucose disposal;
(3) modulation of insulin secretion. For example, Lai
et al. (21) showed ginsenoside Rh2 led to reductions in
plasma glucose levels and an overexpression of the GLUT4
glucose transporter in rats. Wang et al. (22) provided evidence
that ginseng increases aerobic glycolysis through enhancing
the activities of citrate synthetase, malate dehydrogenase
and succinate dehydrogenase, cytochrome oxidase (four
rate-limiting enzymes in aerobic glycolysis). Chung et al. (23)
reported that 50mg/kg aqueous Panax ginseng root body
and rootlets administered for 28 d decreased the activity of
the rate-limiting gluconeogenic enzyme glucose-6-phospha-
tase in liver preparations in diabetic mice by 46 and 20%.
Liu et al. (24) provided evidence that the oral ingestion of
Panax ginseng improved insulin sensitivity that resulted in
the modulation (i.e. lowering) of circulating glucose levels.
In conclusion, the present study suggests that the chronic
ingestion of Panax ginseng has no effect on indices of glucose
regulation in a non-diabetic sample. Additionally, there was
no difference in glucose levels when measured 180min
post-dose. Further research is needed.
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